Ovid Therapeutics Inc. cash flow to debt ratio of -285.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ovid Therapeutics Inc.'s free cash flow has increased -31.58% from $-56.03M last year to $-38.33M, signaling increasing performance

Ovid Therapeutics Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Ovid Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.22 last year to 0.01 today, signaling strengthened financials

Ovid Therapeutics Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Ovid Therapeutics Inc.'s latest filing, so interest coverage cannot be calculated.

Ovid Therapeutics Inc.'s profit margin has increased (-92.73%) in the last year from -4.67K% to -339.33%, signaling increasing performance

Ovid Therapeutics Inc.'s short-term assets of $90.45M exceed its short-term liabilities of $8.29M

Ovid Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ovid Therapeutics Inc.'s return on equity of -22.51%, is lower than 15.00%, indicating bad performance

Ovid Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ovid Therapeutics Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Ovid Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ovid Therapeutics Inc. has negative free cash flow, indicating cash burn

Ovid Therapeutics Inc.'s yearly earnings has increased -34.12% since last year from $-26.43M to $-17.41M, signaling increasing performance

Ovid Therapeutics Inc.'s yearly revenue has increased 1.18K% since last year from $566.00K to $7.25M, signaling increasing performance

ROIC -22.59% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ovid Therapeutics Inc.'s 3-year revenue CAGR of 68.99% is positive, indicating growing revenue over the past 3 years

Ovid Therapeutics Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Ovid Therapeutics Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Ovid Therapeutics Inc. has insufficient data to evaluate this check.

Ovid Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ovid Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ovid Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ovid Therapeutics Inc. is overvalued relative to its fair value price of -24.41 based on Earnings Fair Value model

Ovid Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ovid Therapeutics Inc. has a price-to-book ratio of 0.97x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Ovid Therapeutics Inc. has a price-to-sales ratio of 27.12x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue